NeuroOne Medical Technologies Corporation (NMTC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (-4.39% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #701 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).
Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.5% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NMTC currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($0.98) forces dealer call-delta covering toward $6.43.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NeuroOne Medical Technologies Corporation (NMTC) dropped -4.39% to $0.93, trading at 3% of its 52-week range ($0.77 – $6.12). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Dist
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today
NeuroOne’s FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corpo
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +163.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NMTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NMTC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroOne Medical Technologies Corporation (NMTC) ranks #701 by composite RQD confidence (33/100, grade E) and #907 by equity capitalization ($8.4M). Within this direct 5-issuer industry benchmark cohort, NMTC leads on earnings valuation at N/A trailing P/E, while NMTC leads on capital efficiency and profitability with -35.0% ROIC and 56.5% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NMTC at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NMTC
ACTIVE
NeuroOne Medical Technologies Corporation | E | 33/100 | — | 56.5% | -35.0% | -4.39% | $8.4M | Benchmark Subject |
| AEMD Aethlon Medical Inc. | D- | 36/100 | — | — | -35.0% | -1.45% | $8.7M | /aemd-vs-nmtc → |
| PLSM Pulsenmore Ltd. | D | 47/100 | — | — | — | +3.09% | $10.9M | /plsm-vs-nmtc → |
| FEMY Femasys Inc. | E | 30/100 | — | 62.0% | -35.0% | +1.11% | $11.5M | /femy-vs-nmtc → |
| ICU SeaStar Medical Holding Corporation | E | 31/100 | — | 95.7% | -35.0% | -3.03% | $11.8M | /icu-vs-nmtc → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported GAAP revenue of $9.1M (+163.5% vs. FY2024 revenue of $3.5M , and +366.0% cumulative change since FY2023) , GAAP net income of -$3.6M, operating cash flow of -$2.8M, and free cash flow of -$2.9M (+73.8% YoY). On the balance sheet, NMTC closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $9.1M | -$3.6M | -$2.8M | -$2.9M | $8.6M | — |
| FY2024 (FY) | 2024-09-30 | $3.5M | -$12.3M | -$11.0M | -$11.1M | $6.5M | — |
| FY2023 (FY) | 2023-09-30 | $2.0M | -$11.9M | -$12.9M | -$12.9M | — | — |
As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (-4.39% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #701 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).
Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NMTC last traded at $0.93 (-4.39% on volume of 33,829 shares), positioning the stock -27.34% below its 50-day simple moving average ($1.28) and -70.57% below its 200-day simple moving average ($3.16). Across its 52-week range of $0.77 to $6.12, NMTC sits at the 3.0% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).
Why NMTC Stock dropped -4.39% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, NMTC scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the valuation tradeoff is that a stock trading at $0.97 with an $8.8M market capitalization is priced as a speculative, high-variance situation. The upside drivers would need to come from a turnaround in operating economics, which the current rating does not support. The principal risk is that weak cash generation and low institutional and insider conviction leave little cushion if the company must raise capital or if revenue growth does not convert to earnings.
NeuroOne Medical Technologies Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company is a medical technology operator with a market capitalization of $0.0B as presented in the profile field. The source data does not itemize specific products, customers, or revenue model beyond reported revenue figures. Per the recent news wire, the company is associated with a brain drug-delivery platform that received a first order from a drugmaker, and a reported record $4.5 Million order.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $9.1M | $-4.2M | $-3.6M | N/A | $-2.9M | $3.6M | N/A |
| FY 2024 | $3.5M | $-11.9M | $-12.3M | N/A | $-11.1M | $1.1M | N/A |
| FY 2023 | $2.0M | $-12.0M | $-11.9M | N/A | $-12.9M | N/A | N/A |
Per the market data, gross margin is 56.5%, operating margin -46.5%, and net margin -39.6%, with ROIC of -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with Debt/Equity of 0.5. Revenue rose from $2.0M in FY 2023 to $9.1M in FY 2025, but operating losses persisted in every reported period, and cash moved from $1.1M to $3.6M over FY 2024–FY 2025.
Per the recent news wire, the most significant catalyst is a Quiver Quantitative report (GREEN, CATALYST) describing preliminary fiscal Q4 and full-year 2026 product revenue growth that topped guidance with a record $4.5 Million order. Other items (YELLOW, MARKET WIRE) are aggregator and forum coverage of NMTC market action and a Stock Titan item on a brain drug-delivery platform's first drugmaker order. These headlines are generic in summary text; the substantive fact in the record is the order and revenue commentary. Watch items include whether the order and growth translate into sustained cash flow, given the reported operating losses. The Butterfly supply-chain graph reports no proprietary signals.
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. A prospective investor should monitor whether the drugmaker order relationship expands into recurring demand, since that would be the primary second-order dependency suggested by the news wire, but the graph does not map it.
Real-time company headlines, analyst actions, and sector developments for NeuroOne Medical Technologies Corporation (NMTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeuroOne Medical Technologies Corporation (NMTC) market action, institutional positioning, and fundamental catalysts.
Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Dist
Welcome to the NMTC (NeuroOne Medical Technologies Corporation) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on NMTC, but look at what you are paying: current EV/EBITDA multiples with 56.5% gross margins. Unless NeuroOne Medical Technologies Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on NMTC, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.97 (52-wk range $0.77 - $6.12), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).